What's the best way to lose weight, following a diet or taking drugs like Ozempic?
The importance of combating the social stigma around obesity and overweight while incorporating new drugs like GLP-1 agonists into comprehensive treatment plans.
How 'miracle' weight-loss drugs will change the world
GLP-1 agonists could lead to a healthier society by reducing obesity and related health issues by 2030.
Weight-loss drugs could be key in lowering US obesity rates experts
Weight-loss drugs like GLP-1 agonists may play an essential role in reducing obesity rates and improving overall health outcomes in the US.
New Weight-Loss Drugs Are Meant to Be Lifelong. What Happens When You Quit?
Weight-loss drugs like Wegovy and Ozempic are popular but many users quit due to factors like cost, side effects, and limited coverage.
What's the best way to lose weight, following a diet or taking drugs like Ozempic?
The importance of combating the social stigma around obesity and overweight while incorporating new drugs like GLP-1 agonists into comprehensive treatment plans.
How 'miracle' weight-loss drugs will change the world
GLP-1 agonists could lead to a healthier society by reducing obesity and related health issues by 2030.
Weight-loss drugs could be key in lowering US obesity rates experts
Weight-loss drugs like GLP-1 agonists may play an essential role in reducing obesity rates and improving overall health outcomes in the US.
New Weight-Loss Drugs Are Meant to Be Lifelong. What Happens When You Quit?
Weight-loss drugs like Wegovy and Ozempic are popular but many users quit due to factors like cost, side effects, and limited coverage.
Is Ozempic an Obesity Drug, or an Everything Drug?
The weekly shots, such as GLP-1 agonists, used for weight loss can have various health benefits beyond shedding pounds.
What To Do If Your Teen Asks To Go On Ozempic, According To Doctors
The popularity of Ozempic reflects societal obsessions with weight loss, impacting conversations around body image and health, especially for younger generations.
GLP-1 Agonists May Help Treatment of Mental Illness and Substance Use
GLP-1 agonists, like semaglutide, are effective for weight loss but their high prices hinder accessibility and public health benefits.
The Longest Clinical Trial Yet Of Blockbuster Weight Loss Drug Wegovy Reveals Significant Side Effects
GLP-1 agonists like Wegovy show significant weight loss and may have long-lasting effects, but concerns exist regarding side effects.
When Ozempic fails: Study sheds light on why some patients lose half as much weight as others
Genetic analysis can predict patient's response to semaglutide for weight loss, not effective for everyone.
Many patients keep weight off after stopping anti-obesity meds: study
Patients on GLP-1 agonist medications for obesity may keep some weight off even after stopping the medication.
The new data provides a more nuanced picture of patient outcomes and contradicts previous studies suggesting that patients need to stay on the medication to maintain weight loss.
Is Ozempic an Obesity Drug, or an Everything Drug?
The weekly shots, such as GLP-1 agonists, used for weight loss can have various health benefits beyond shedding pounds.
What To Do If Your Teen Asks To Go On Ozempic, According To Doctors
The popularity of Ozempic reflects societal obsessions with weight loss, impacting conversations around body image and health, especially for younger generations.
GLP-1 Agonists May Help Treatment of Mental Illness and Substance Use
GLP-1 agonists, like semaglutide, are effective for weight loss but their high prices hinder accessibility and public health benefits.
The Longest Clinical Trial Yet Of Blockbuster Weight Loss Drug Wegovy Reveals Significant Side Effects
GLP-1 agonists like Wegovy show significant weight loss and may have long-lasting effects, but concerns exist regarding side effects.
When Ozempic fails: Study sheds light on why some patients lose half as much weight as others
Genetic analysis can predict patient's response to semaglutide for weight loss, not effective for everyone.
Many patients keep weight off after stopping anti-obesity meds: study
Patients on GLP-1 agonist medications for obesity may keep some weight off even after stopping the medication.
The new data provides a more nuanced picture of patient outcomes and contradicts previous studies suggesting that patients need to stay on the medication to maintain weight loss.
Weight loss drug market shows impressive growth, driven by GLP-1 agonists.
New potential applications for these drugs could significantly expand the market.
Positive investor sentiment around biotech companies focused on weight loss drugs.
Ozempic Gets the Oprah Treatment in a New TV Special
Weight-loss drugs like Ozempic, Wegovy, and Zepbound are becoming increasingly popular.
Oprah Winfrey's support for weight-loss medications in her ABC special may further boost the popularity of these drugs.
Obesity drugs aren't always forever. What happens when you quit?
GLP-1 agonists are popular weight-loss drugs, but many people discontinue due to cost, side effects, and other factors. Stopping these medications can lead to weight regain.
3 GLP-1 Stocks to Buy Now For Big Long-Term Gains
Weight loss drug market shows impressive growth, driven by GLP-1 agonists.
New potential applications for these drugs could significantly expand the market.
Positive investor sentiment around biotech companies focused on weight loss drugs.
Ozempic Gets the Oprah Treatment in a New TV Special
Weight-loss drugs like Ozempic, Wegovy, and Zepbound are becoming increasingly popular.
Oprah Winfrey's support for weight-loss medications in her ABC special may further boost the popularity of these drugs.
Obesity drugs aren't always forever. What happens when you quit?
GLP-1 agonists are popular weight-loss drugs, but many people discontinue due to cost, side effects, and other factors. Stopping these medications can lead to weight regain.
Doctors grapple with patients' demand for weight-loss drugs
Primary care doctors are facing an influx of requests for anti-obesity drugs, including from patients who may not necessarily need them.
The demand for GLP-1 agonist drugs, such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound, is expected to increase after new data shows their potential in reducing heart problems.
There is a need for balanced consideration of other treatments and interventions before resorting to these drugs, as not everyone may require them.